No. The process is different from the one for the vaccine that was used to combat the pandemic. Production capacity was geared to the entire population, which is not the case now. This case involves manufacturing a vaccine intended for clinical trials. That is very different. It involves the science and the means of production.
In the case of the H1N1 virus, there was a consultation with the provinces, experts and others. We have production capacity here in Canada, and that is very important. The value of it was clear during the pandemic. However, we are also considering other possibilities.